

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute myelogenous leukemia (AML)	Integrin β_3 (GPIIIa; CD61)	Studies in mice suggest antagonizing CD61 could help treat AML. In a mouse xenograft model for AML, knockdown or deletion of <i>Cd61</i> slowed leukemia progression and increased survival compared with wild-type <i>Cd61</i> expression without affecting hematopoiesis. Next steps could include testing anti-CD61 mAbs in mouse models for AML.	Patent and licensing status undisclosed	Miller, P.G. <i>et al. Cancer Cell</i> ; published online June 13, 2013; doi:10.1016/j.ccr.2013.05.004 Contact: Benjamin L. Ebert, Harvard Medical School, Boston, Mass. e-mail: bebert@partners.org
<p><i>SciBX</i> 6(29); doi:10.1038/scibx.2013.747 Published online Aug. 1, 2013</p>				